RD-162 is a second-generation nonsteroidal antiandrogen (NSAA) which was developed for the treatment of prostate cancer but was never marketed.

[1] It acts as a potent and selective silent antagonist of the androgen receptor (AR).

[1] Both RD-162 and enzalutamide show 5- to 8-fold higher affinity for the AR than the first-generation NSAA bicalutamide, and only 2- to 3-fold lower affinity than dihydrotestosterone (DHT), the major endogenous ligand of the receptor in the prostate gland.

[1] Enzalutamide was ultimately selected from the two for further clinical development and was eventually marketed.

This drug article relating to the genito-urinary system is a stub.